vimarsana.com

Page 59 - Diffuse Largeb Cell Lymphoma News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Investegate |NOVARTIS AG CHF0 50(REGD) Announcements | NOVARTIS AG CHF0 50(REGD): Novartis announces T-Charge™, next-generation CAR-T platform with first-in-human data at ASH 2021

Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis announces T-Charge™, next-generation CAR-T platform with first-in-human data at ASH 2021

United statesIsabella zinckJay bradnerIanw flinnThomas hungerbuehlerSamir shahParag mahantiJulie masowSloan simpsonAlina levchukFiona phillipsNovartis institutes for biomedical researchNovartis oncology communicationsNovartis us external communicationsNovartis external communicationsExchange commission

Investegate |F Hoffmann-La Roche Ltd Announcements | F Hoffmann-La Roche Ltd: Roche presents pivotal data at ASH 2021 for novel cancer immunotherapy mosunetuzumab

Investegate announcements from F. Hoffmann-La Roche Ltd, Roche presents pivotal data at ASH 2021 for novel cancer immunotherapy mosunetuzumab

United statesNathalie meetzPolatuzumab vedotinMosunetuzumab monotherapyLevi garrawayGazyva gazyvaroGlofitamab glofitLoren kalmPolatuzumab vedotin polaDrug administrationHead of global product developmentAmerican society of hematologyRoche groupEuropean medicines agencyRoche group media relationsAmerican society

MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of T

DGAP-News: MorphoSys AG / Key word(s): Miscellaneous/Conference11.12.2021 / 18:00 The issuer is solely responsible for the content of this announcement.MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi(R)) in Combination with Lenalidomide for the Treatme.

United statesGrzegorz nowakowskiPeter langmuirNuwan kurukulasuriyaTafasitamab monjuviPractice research clinical haematologyJanssen biotech incAmerican society of hematology annual meetingXencor incGroup viceDrug administrationGlobal head of medical affairsJanssen research developmentMorphosys us incDistribution servicesExchange commission

F Hoffmann-La Roche Ltd: Roche presents pivotal data at ASH 2021 for novel cancer immunotherapy mosunetuzumab

Results to be presented for the first time show mosunetuzumab induces high and durable complete response rates in people with follicular lymphoma who have received two or more prior therapies1New efficacy

United statesNathalie meetzMosunetuzumab monotherapyLevi garrawayKarl mahlerMabthera rituxanGazyva gazyvaroSabine borngrGerard tobinBruno eschliVenclexta venclyxtoGlofitamab glofitBirgit masjostLoren kalmPolatuzumab vedotin polaDrug administration

MorphoSys AG: MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

- RE-MIND2 compared patient outcomes from pivotal L-MIND study with matched patient populations treated with NCCN/ESMO recommended therapies- Results from the retrospective cohort analysis indicate significant

United statesGrzegorz nowakowskiPeter langmuirNuwan kurukulasuriyaPractice research clinical haematologyJanssen biotech incAmerican society of hematology annual meetingXencor incGroup viceDrug administrationGlobal head of medical affairsJanssen research developmentMorphosys us incExchange commissionMeeting of the society hematologic oncologyEuropean medicines agency

vimarsana © 2020. All Rights Reserved.